ABSTRACT
Zinc deficiency is a risk factor for the development of obesity and diabetes. Studies have shown lower serum zinc levels in obese individuals and those with diabetes. We speculate that zinc supplementation can alleviate obesity and diabetes and, to some extent, their complications. To test our hypothesis, we investigated the effects of zinc supplementation on mice with high-fat diet (HFD)-induced hepatic steatosis in vivo and in vitro by adding zinc to the diet of mice and the medium of HepG2 cells. Both results showed that high levels of zinc could alleviate the glucose and lipid metabolic disorders induced by a HFD. High zinc can reduce glucose production, promote glucose absorption, reduce lipid deposition, improve HFD-induced liver injury, and regulate energy metabolism. This study provides novel insight into the treatment of non-alcoholic fatty liver disease and glucose metabolic disorder.
Subject(s)
Glucose Metabolism Disorders/drug therapy , Glucose/metabolism , Lipid Metabolism/drug effects , Zinc/administration & dosage , Animals , Diet, High-Fat/adverse effects , Dietary Supplements/analysis , Energy Metabolism/drug effects , Glucose Metabolism Disorders/etiology , Glucose Metabolism Disorders/metabolism , Humans , Liver/metabolism , Male , Mice , Mice, Inbred C57BLABSTRACT
Functional oligosaccharides, particularly konjac mannan oligosaccharides (KMOS), can regulate glucose metabolism. However, the molecular mechanisms involved in the hypoglycemic effect of KMOS remain largely unknown. Here, the effect of KMOS supplementation on glucose homeostasis was evaluated in both high-fat diet (HFD)-fed C57BL/6J mice and high-glucosamine-induced HepG2 cells. KMOS supplementation remarkably ameliorated the fasting blood glucose, glucose tolerance, and insulin tolerance of HFD-fed mice. Abnormalities of triglyceride and glycogen metabolism in the liver induced by the HFD were reversed by KMOS supplementation. The insulin signaling pathway was activated by KMOS, with stimulation of GLUT2 membrane translocation and glucose uptake in HepG2 cells via the AMPK pathway. Moreover, KMOS suppressed p-mTOR expression and stimulated the GSK-3ß/CREB pathway via the AMPK pathway. KMOS significantly upregulated leptin receptor expression and downregulated PTP1B and SOCS3 levels in the liver and brain, with a decreased serum leptin concentration. Phosphorylation of JAK2 and STAT3 in the liver was activated by KMOS supplementation, while the expressions of Sirt1, Tfam, and Pgc1-α in the brain were elevated. Conclusively, KMOS attenuated HFD-induced glucose metabolism dysfunction through the regulation of insulin resistance and leptin resistance. This finding indicates that KMOS have potential value as an anti-hyperglycemic dietary supplement.
Subject(s)
Blood Glucose/drug effects , Dietary Supplements , Glucose Metabolism Disorders/drug therapy , Hepatocytes/drug effects , Hypoglycemic Agents/pharmacology , Insulin Resistance , Insulin/blood , Leptin/metabolism , Liver/drug effects , Mannans/pharmacology , Animals , Biomarkers/blood , Blood Glucose/metabolism , Diet, High-Fat , Disease Models, Animal , Glucose Metabolism Disorders/blood , Glucose Metabolism Disorders/etiology , Hep G2 Cells , Hepatocytes/metabolism , Homeostasis , Humans , Liver/metabolism , Male , Mice, Inbred C57BL , Signal TransductionSubject(s)
Heart/diagnostic imaging , Iron Overload/diagnostic imaging , Liver/diagnostic imaging , Myocardium/pathology , Pancreas/diagnostic imaging , beta-Thalassemia/pathology , Adult , Chelation Therapy , Combined Modality Therapy , Endocrine System Diseases/etiology , Erythrocyte Transfusion/adverse effects , Female , Follow-Up Studies , Glucose Metabolism Disorders/epidemiology , Glucose Metabolism Disorders/etiology , Heart Diseases/etiology , Humans , Incidence , Iron Chelating Agents/therapeutic use , Iron Overload/drug therapy , Iron Overload/etiology , Iron Overload/pathology , Liver/pathology , Liver Cirrhosis/etiology , Magnetic Resonance Imaging/methods , Male , Organ Specificity , Pancreas/pathology , Splenectomy , beta-Thalassemia/complications , beta-Thalassemia/therapyABSTRACT
Tetragonia tetragonioides (Pall.) Kuntze (TTK) and JakYakGamCho-Tang (JGT) have been used for improving women's health and treating inflammatory diseases. We determined that the long-term consumption of these herbal extracts alleviates the progression of postmenopausal symptoms in high-fat-diet fed ovariectomized (OVX) rats, and further explored the mechanisms involved. Five groups of OVX rats were fed high fat diets that were supplemented with either 2% dextrin (control), 2% TTK (70% ethanol extract), 2% JGT (water extract), 1% JGT + 1% TTK (JGTT), or 30 µg/kg body weight/day of 17ß-estradiol (positive control). After eight weeks of dietary intervention, the herbal treatments did not change the serum concentrations of 17ß-estradiol or uterine weight in control rats, but they were higher in the positive-control group. TTK rats exhibited higher daily energy expenditure, particularly fat oxidation, without modifying the energy intake than the controls. TTK lowered the fat mass but lean body mass of the abdomen and leg were increased. JGT decreased periuterine fat mass and lean body mass more than the control but the decrease was not as much as TTK. TTK resulted in substantially lower serum concentrations of the proinflammatory cytokines, tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1, than the control and JGT had lesser effect than TTK. Insulin resistance, determined by homeostasis model assessment estimate for assessing insulin resistance (HOMA-IR) and insulin tolerance test, was reduced in the decreasing order of control, JGT, JGTT, and TTK and the HOMA-IR of TTK was similar to the positive control. TTK, but not JGT, enhanced glucose tolerance compared with the control, although the serum insulin levels in TTK were lower compared to the control. Interestingly, the ß-cell masses were much greater in the TTK and JGTT groups than in the control, and they were comparable to the positive control. The increases in ß-cell masses in TTK and JGTT groups were associated with enhanced ß-cell proliferation and suppressed apoptosis, which was related to the decreased TNF-α and interleukin-1ß expressions. In conclusion, JGTT did not improve menopausal symptoms better than TTK itself. TTK itself prevented the OVX-induced impairments in energy, lipid, and glucose metabolism, similar to the positive control, without changing serum 17ß-estradiol levels and potentiating insulin signaling and decreasing proinflammatory cytokines. TTK may be a useful intervention to alleviate some menopausal symptoms similar to selective estrogen receptor modulators and should be investigated with further human study. Impact statement Menopause decreases the quality of life in middle-aged women and herbal remedies are sometimes used as alternatives for hormone replacement therapy, which may have detrimental side effects. Although several herbal extracts have been studied, no remedies improve all the menopausal symptoms. In this study, the 70% ethanol extract of Tetragonia tetragonioides (Pall.) Kuntze (TTK) reduced the symptoms of hot flushes and improved energy, glucose, and lipid metabolism in estrogen-deficient animals without increasing serum 17ß-estradiol levels. This extract acts like a selective estrogen receptor modulator and it may be a useful intervention for alleviating menopausal symptoms. This is the first study to show that the 70% ethanol extract of TTK has the potential to treat menopause-associated symptoms and metabolic disturbances. It may be a useful intervention for alleviating the symptoms of menopause in women if its efficacy can be confirmed in human studies.
Subject(s)
Aizoaceae , Energy Metabolism/drug effects , Estrogens/deficiency , Glucose Metabolism Disorders/drug therapy , Phytotherapy/methods , Plant Extracts/therapeutic use , Aizoaceae/chemistry , Animals , Calorimetry , Energy Metabolism/physiology , Female , Glucose Metabolism Disorders/etiology , Ovariectomy , Rats , Rats, Sprague-DawleyABSTRACT
Inhibition of the mTOR (mechanistic target of rapamycin) signaling pathway by the FDA-approved drug rapamycin promotes life span in numerous model organisms and delays age-related disease in mice. However, the utilization of rapamycin as a therapy for age-related diseases will likely prove challenging due to the serious metabolic and immunological side effects of rapamycin in humans. We recently identified an intermittent rapamycin treatment regimen-2mg/kg administered every 5 days-with a reduced impact on glucose homeostasis and the immune system as compared with chronic treatment; however, the ability of this regimen to extend life span has not been determined. Here, we report for the first time that an intermittent rapamycin treatment regimen starting as late as 20 months of age can extend the life span of female C57BL/6J mice. Our work demonstrates that the anti-aging potential of rapamycin is separable from many of its negative side effects and suggests that carefully designed dosing regimens may permit the safer use of rapamycin and its analogs for the treatment of age-related diseases in humans.
Subject(s)
Aging , Longevity , Signal Transduction , Sirolimus , TOR Serine-Threonine Kinases/metabolism , Aging/drug effects , Aging/physiology , Animals , Drug Administration Schedule , Drug Chronotherapy , Female , Glucose Metabolism Disorders/etiology , Glucose Metabolism Disorders/prevention & control , Immune System/drug effects , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/metabolism , Longevity/drug effects , Longevity/physiology , Mice , Mice, Inbred C57BL , Signal Transduction/drug effects , Signal Transduction/physiology , Sirolimus/administration & dosage , Sirolimus/adverse effects , Sirolimus/metabolism , Treatment OutcomeABSTRACT
CONTEXT: Endocrine problems are common in patients with Fanconi anemia (FA). About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility. The goal of this report is to provide an overview of endocrine abnormalities and guidelines for routine screening and treatment to allow early diagnosis and timely intervention. EVIDENCE ACQUISITION: This work is based on a comprehensive literature review, including relevant articles published between 1971 and 2014, and proceedings of a Consensus Conference held by the Fanconi Anemia Research Fund in 2013. EVIDENCE SYNTHESIS: The panel of experts collected published evidence and discussed its relevance to reflect current information about the endocrine care of children and adults with FA before the Consensus Conference and through subsequent deliberations that led to the consensus. CONCLUSIONS: Individuals with FA should be routinely screened for endocrine abnormalities, including evaluation of growth; glucose, insulin, and lipid metabolism; thyroid function; puberty; gonadal function; and bone mineral metabolism. Inclusion of an endocrinologist as part of the multidisciplinary patient care team is key to providing comprehensive care for patients with FA.
Subject(s)
Endocrine System Diseases/diagnosis , Endocrine System Diseases/therapy , Fanconi Anemia/diagnosis , Fanconi Anemia/therapy , Mass Screening/standards , Practice Guidelines as Topic , Adult , Child , Endocrine System Diseases/etiology , Fanconi Anemia/complications , Glucose Metabolism Disorders/diagnosis , Glucose Metabolism Disorders/etiology , Glucose Metabolism Disorders/therapy , Growth Disorders/diagnosis , Growth Disorders/etiology , Growth Disorders/therapy , Human Growth Hormone/deficiency , Human Growth Hormone/therapeutic use , Humans , Malnutrition/diagnosis , Malnutrition/etiology , Malnutrition/therapy , Mass Screening/methods , Thinness/diagnosis , Thinness/etiology , Thinness/therapyABSTRACT
The aim of this study was to determine whether the Rehmannia glutinosa oligosaccharides (ROS) ameliorate the impaired glucose metabolism and the potential mechanism in chronic stress rats fed with high-fat diet. The rats were fed by a high-fat diet and simultaneously stimulated by chronic stress over 5 weeks. Body weight, fasting plasma glucose, intraperitoneal glucose tolerance test (IPGTT), plasma lipids, gluconeogenesis test (GGT), glycogen content, and corticosterone, insulin and leptin levels were measured. The results showed that ROS administration (100, 200 mg/kg, i.g.) for 5 weeks exerted the effects of increasing the organ weights of thymus and spleen, lowering the fasting plasma glucose level, improving impaired glucose tolerance, increasing the contents of liver and muscle glycogen, decreasing the gluconeogenesis ability, plasma-free fatty acid's level, as well as plasma triglyceride and total cholesterol levels in chronic stress and high-fat fed rats, especially in the group of 200mg/kg; while the plasma corticosterone level was decreased, and plasma leptin level was increased. These results suggest that ROS exert an ameliorating effect of impaired glucose metabolism in chronic stress rats fed with high-fat diet, and the potential mechanism may be mediated through rebuilding the glucose homeostasis in the neuroendocrine immuno-modulation (NIM) network through multilinks and multitargets.
Subject(s)
Glucose Metabolism Disorders/drug therapy , Oligosaccharides/therapeutic use , Phytotherapy , Reactive Oxygen Species/metabolism , Rehmannia , Animals , Blood Glucose/metabolism , Corticosterone/blood , Diet, High-Fat/adverse effects , Drug Evaluation, Preclinical , Glucose Metabolism Disorders/etiology , Glucose Metabolism Disorders/metabolism , Glucose Tolerance Test , Glycogen/metabolism , Insulin/blood , Leptin/blood , Lipids/blood , Liver/metabolism , Male , Muscles/metabolism , Oligosaccharides/pharmacology , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Plants, Medicinal , Random Allocation , Rats, Wistar , Stress, Psychological/complications , Stress, Psychological/metabolismABSTRACT
Schizophrenia (SCZ) is the result of DNA alterations and environmental factors, which together lead to differential protein expression and ultimately to the development of the illness. The diagnosis is based on clinical symptoms, and the molecular background of SCZ is not completely understood. The thalamus, whose dysfunction has been associated with SCZ based in diverse lines of evidences, plays for instance a pivotal role in the central nervous system as a relay center by re-distributing auditory and visual stimuli from diverse brain regions to the cerebral cortex. We analyzed the proteome of postmortem mediodorsal thalamus (MDT) samples from 11 SCZ patients and 8 non-SCZ individuals by using quantitative shotgun-mass spectrometry and two-dimensional gel electrophoresis. Our analyses identified 551 proteins, 50 of which showed significant differential expression. The main pathways affected by the differentially expressed proteins include energy metabolism, oligodendrocyte metabolism, and cytoskeleton assembly. The potential protein biomarkers candidates myelin basic protein and myelin oligodendrocyte protein were validated by Western blot in the MDT samples and also in cerebrospinal fluid from a separate set of samples of 17 first-episode SCZ patients and 10 healthy controls. The differential expression of µ-crystallin, protein kinase C-gamma, and glial fibrillary acidic protein were confirmed in MDT. Because we found several glycolysis enzymes to be differentially expressed, we measured the levels of pyruvate and NADPH and found them to be altered in MDT. The protein changes described here corroborate the importance of myelin/oligodendrocyte and energy metabolism in SCZ and highlight new potential biomarkers candidates that may contribute to the understanding of the pathogenesis of this complex disease.
Subject(s)
Biomarkers/analysis , Glucose Metabolism Disorders/etiology , Glycolysis/physiology , Proteome/analysis , Schizophrenia , Thalamus/metabolism , Adult , Aged , Aged, 80 and over , Analysis of Variance , Biomarkers/metabolism , Chromatography, High Pressure Liquid/methods , Electrophoresis, Gel, Two-Dimensional , Female , Humans , Isoelectric Focusing/methods , Male , Mass Spectrometry , Middle Aged , NADP/metabolism , Proteome/metabolism , Proteomics/methods , Pyruvic Acid/metabolism , Schizophrenia/cerebrospinal fluid , Schizophrenia/complications , Schizophrenia/pathology , Young AdultABSTRACT
Interest in the physiologic and pharmacologic role of bioactive compounds present in plants has increased dramatically over the last decade. Of particular interest in relation to human health are the classes of compounds known as the phytoestrogens, which embody several groups of non-steroidal estrogens, including isoflavones and lignans that are widely distributed within nature. The impact of dietary phytoestrogens on normal biologic processes was first recognized in sheep. Observations of sheep grazing on fields rich in clover and cheetahs fed high soy diets in zoos suggested that flavonoids and related phytochemicals can affect mammalian health. Endogenous estrogens have an important role not only in the hypothalamic-pituitary-gonadal axis, but also in various non-gonadal systems, such as cardiovascular systems, bone, and central nervous systems, and lipid metabolism. There have been several clinical studies of hormone replacement therapy (HRT) in post-menopausal women to examine whether HRT has beneficial effects on the cardiovascular system, bone fractures, lipid metabolism, and Alzheimer's disease. In addition, estrogen contributes to the development of some estrogen-dependent cancers, such as breast cancer and prostate cancer and the number of patients with these cancers is increasing in developed countries. Although recent mega-studies showed negative results for classical HRT in the prevention of some of these diseases, the molecules that interact with estrogen receptors are candidate drugs for various diseases, including hormone-dependent cancers. This review focuses on the molecular properties and pharmaceutical potential of phytoestrogens.
Subject(s)
Alzheimer Disease/prevention & control , Breast Neoplasms/prevention & control , Cardiovascular Diseases/prevention & control , Glucose Metabolism Disorders/prevention & control , Osteoporosis/prevention & control , Phytoestrogens/therapeutic use , Alzheimer Disease/etiology , Animals , Breast Neoplasms/etiology , Cardiovascular Diseases/etiology , Dietary Supplements , Female , Glucose Metabolism Disorders/etiology , Hormone Replacement Therapy , Humans , Isoflavones/pharmacology , Isoflavones/therapeutic use , Osteoporosis/etiology , Phytoestrogens/pharmacology , Postmenopause/drug effects , Postmenopause/physiology , Receptors, Estrogen/drug effects , Receptors, Estrogen/physiology , SheepABSTRACT
Metabolic syndrome also can be named insulin resistance syndrome. The main clinical manifestations include metabolic disorders of glucose and lipid and some diseases caused by the metabolic disorder, such as impaired glucose tolerance or diabetes, obesity, hyperlipemia, fatty liver, hypertension, coronary heart disease, microalbuminuria, etc. According to the theory of zang-fu organs (viscera) in traditional Chinese medicine, these diseases all result from the deficiency of spleen-qi. They are characterized by deficiency in the Ben (root) and excess in the Biao (branch). The Ben (root) is the failure of the spleen in transportation, and the Biao (branch) is stagnation of qi, blood, phlegm, fire, dampness and food. In the prevention and treatment of metabolic syndrome, it is advocated that the intervention of medicine should be used as early as possible, so as to slow down the occurrence and development of insulin resistance, and that emphasis should be transferred from decreasing blood glucose alone to comprehensive prevention of risk factors, especially to the prevention of cardiovascular events. The effect of traditional Chinese herbs is not as good as the western drugs in decreasing the blood pressure and glucose. However, the traditional Chinese herbs have distinctive superiority in ameliorating the insulin resistance, protecting the injury of vascular endothelial cells, regulating the metabolism of lipid, inhibiting the hypercoagulability, and treating the inflammation. Moreover, they are relatively safe. Therefore, the integration of the traditional Chinese medicine and western medicine is worth further research.